1. Home
  2. MLYS vs CLOV Comparison

MLYS vs CLOV Comparison

Compare MLYS & CLOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

N/A

Current Price

$28.41

Market Cap

2.3B

Sector

Health Care

ML Signal

N/A

Logo Clover Health Investments Corp.

CLOV

Clover Health Investments Corp.

N/A

Current Price

$4.24

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MLYS
CLOV
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
MLYS
CLOV
Price
$28.41
$4.24
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$48.67
$2.90
AVG Volume (30 Days)
841.5K
3.4M
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
37.43
38.03
EPS
N/A
0.10
Revenue
N/A
$1,924,308,000.00
Revenue This Year
N/A
$52.59
Revenue Next Year
N/A
$15.37
P/E Ratio
N/A
$42.55
Revenue Growth
N/A
40.34
52 Week Low
$22.30
$1.58
52 Week High
$47.65
$5.59

Technical Indicators

Market Signals
Indicator
MLYS
CLOV
Relative Strength Index (RSI) 64.18 45.65
Support Level $25.42 $4.09
Resistance Level $31.26 $4.23
Average True Range (ATR) 1.21 0.13
MACD 0.38 0.01
Stochastic Oscillator 95.51 52.24

Price Performance

Historical Comparison
MLYS
CLOV

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CLOV Clover Health Investments Corp.

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Share on Social Networks: